Removal of Remdesivir’s Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19-Reference-Cited by-同舟云学术

Removal of Remdesivir’s Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19

Published:2020-10-20 Issue:11 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Lê Minh Patrick¹²^ORCID,Le Hingrat Quentin³⁴^ORCID,Jaquet Pierre⁵,Wicky Paul-Henri⁵,Bunel Vincent⁶,Massias Laurent¹⁴,Visseaux Benoit³⁴^ORCID,Messika Jonathan⁶,Descamps Diane³⁴,Mal Hervé⁶,Timsit Jean-François⁴⁵,Peytavin Gilles¹⁴^ORCID

Affiliation:

1. AP-HP, Bichat Claude Bernard Hospital, Pharmacology-Toxicology Department, Paris, France

2. INSERM, UMRS 1144, Université de Paris, Paris, France

3. AP-HP, Bichat Claude Bernard Hospital, Virology Department, Paris, France

4. IAME, INSERM, UMRS 1137, Université de Paris, Paris, France

5. AP-HP, Bichat Claude Bernard Hospital, Medical and Infectious Diseases ICU (MI2), Paris, France

6. AP-HP, Bichat Claude Bernard Hospital, Pneumology B and Lung Transplant Department, INSERM 1152, Paris, France

Abstract

Remdesivir has reported efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro and in vivo . Drug-drug interactions limit therapeutic options in transplant patients. Remdesivir and its metabolite GS-441524 are excreted principally in urine. In intensive care unit (ICU) settings, in which multiple-organ dysfunctions can occur rapidly, hemodialysis may be a viable option for maintaining remdesivir treatment, while improving tolerance, by removing both remdesivir’s metabolite (GS-441524) and sulfobutylether β-cyclodextrin sodium (SEBCD).

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01521-20

Reference10 articles.

1. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

2. Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

3. Care for Critically Ill Patients With COVID-19

4. Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease

5. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and effectiveness of remdesivir for the treatment of COVID-19 patients with end-stage renal disease: A retrospective cohort study;Journal of Microbiology, Immunology and Infection;2023-12

2. Facile Synthesis of Substituted Pyrroles Using Silica Supported Catalysis;Organic Preparations and Procedures International;2023-10-06

3. Pharmacokinetics of GS-441524, the active metabolite of remdesivir, in patients receiving continuous renal replacement therapy: A case series;Journal of Infection and Chemotherapy;2023-10

4. Monkeypox 2022: What clinicians in the dialysis community should do;Hemodialysis International;2022-10-09

5. The Pharmacist’s Role in Managing COVID-19 in Chronic Kidney Disease Patients: A Review of Existing Strategies and Future Implications;Pharmacy;2022-08-05